Systemic lupus erythematosus (SLE) is a complex, chronic, autoimmune disorder that involves multiple organ systems including the skin, joints, heart, lungs, blood, kidneys and, in the most severe ...
After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...
Anifrolumab can substantially lower the risk for long-term organ damage progression in patients with moderate to severe active lupus, a retrospective study shows.
More than one-third of patients with systemic lupus erythematosus experience a flare after starting dialysis for end-stage ...
Assistant Professor Andrew Monteith's lab in the Department of Microbiology is documenting how key immune cells detect ...
However, symptoms often overlap with those of systemic lupus erythematosus (SLE). These include: muscle and joint pain sometimes with swelling flu-like symptoms of fatigue and fever serositis ...
In a new study, researchers explored experiences, perceptions, and health effects of a newly developed healthy lifestyle ...
The company reported positive phase 2 data from the cohort of cutaneous lupus erythematosus (CLE) patients late last year. Thursday, Merck revealed the systemic lupus erythematosus (SLE ...
New research suggests the use of oral prednisone should be limited in patients with systemic lupus erythematosus with a history of recurrent pericarditis.
CLE may occur in association with systemic lupus erythematosus (SLE). The most common subtypes are discoid (DLE) and subacute (SCLE), accounting for 80% and 16% of cases, respectively. Both TYK2 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback